Aclaris Therapeutics (NASDAQ:ACRS) Downgraded to Sell at StockNews.com

StockNews.com cut shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a research note released on Tuesday morning.

Several other brokerages also recently weighed in on ACRS. HC Wainwright downgraded shares of Aclaris Therapeutics from a buy rating to a neutral rating in a research note on Monday, January 22nd. Cantor Fitzgerald reiterated a neutral rating on shares of Aclaris Therapeutics in a research note on Friday, January 12th. Finally, BTIG Research reiterated a neutral rating on shares of Aclaris Therapeutics in a research note on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Aclaris Therapeutics has a consensus rating of Hold and a consensus price target of $22.25.

Aclaris Therapeutics Stock Performance

Shares of ACRS stock opened at $1.22 on Tuesday. Aclaris Therapeutics has a one year low of $0.59 and a one year high of $11.12. The company has a 50 day moving average price of $1.22 and a 200 day moving average price of $2.45. The firm has a market capitalization of $86.53 million, a price-to-earnings ratio of -0.96 and a beta of 0.22.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.07. Aclaris Therapeutics had a negative net margin of 283.15% and a negative return on equity of 64.56%. The company had revenue of $17.57 million during the quarter, compared to analyst estimates of $3.96 million. As a group, equities analysts forecast that Aclaris Therapeutics will post -0.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Aclaris Therapeutics

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Aclaris Therapeutics by 40.4% during the 4th quarter. Vanguard Group Inc. now owns 4,722,357 shares of the biotechnology company’s stock valued at $4,958,000 after buying an additional 1,359,311 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Aclaris Therapeutics by 90.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 520,880 shares of the biotechnology company’s stock worth $547,000 after purchasing an additional 248,059 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of Aclaris Therapeutics by 4,082.3% in the 4th quarter. GSA Capital Partners LLP now owns 1,587,995 shares of the biotechnology company’s stock worth $1,667,000 after purchasing an additional 1,550,026 shares during the last quarter. Velan Capital Investment Management LP acquired a new position in shares of Aclaris Therapeutics in the 4th quarter worth approximately $1,850,000. Finally, Octagon Capital Advisors LP acquired a new position in shares of Aclaris Therapeutics in the 4th quarter worth approximately $105,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.